Aspen Neuroscience, Inc., a clinical-stage biotechnology company pioneering autologous regenerative therapies, today ...

Mediterranean diet significantly reduces disease severity and improves quality of life in those with mild-to-moderate ...

Personalized, at-home, adaptive deep brain stimulation is safe and effective for patients with moderate-to-advanced Parkinson ...

The Mediterranean diet may improve psoriasis through multiple metabolic and molecular pathways relevant to chronic ...

Despite increasing research on psoriasis overall, data specific to children remain scarce. 1 In 2 systematic literature ...

The phase 2a trial is currently enrolling patients; updated clinical data are expected by the end of 2025. The Food and Drug Administration (FDA) has granted Fast Track designation to troculeucel, an ...

AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that the first European participants have been randomized in ...

Today, Eli Lilly Canada Inc.’s (“Lilly”) Ebglyss® (lebrikizumab) to treat moderate-to-severe atopic dermatitis1 (eczema) has ...

Zunveyl is supplied as 5mg, 10mg, and 15mg delayed-release tablets, which can be taken with or without food. Zunveyl ® (benzgalantamine) is now available for the treatment of mild to moderate dementia ...

Biking is generally a more intense physical activity than walking on flat ground. But other factors can determine which is ...

The EHD outbreak in the Clearwater Region appears to be widespread geographically and moderate in severity, but that could ...